



**SPOT
LIGHT**

KRAS inhibition and dramatic remodeling of the lung tumor microenvironment

FEBE VAN MALDEGEM, PHD



How a novel Imaging Mass Cytometry workflow was optimized for mouse studies

A vast amount of knowledge regarding the human immune system remains undiscovered. Why do some get sick when others don't? Why are there such big differences in cancer diagnosis and progression among patients? What makes immunotherapy treatment work for one person but not another?

Realization about the diversity of cells that make up the immune system is only the beginning of the journey. With advancing technologies that allow us to see into microenvironments down to the single cell, recognition that there is much more to learn has driven scientists to ask harder questions and explore whole systems, integrating the pieces until a broader framework comes to light.

Febe van Maldegem, PhD, and Karishma Valand took the opportunity to apply a new technology to a difficult question, leading to further method advancement and novel insights into the mechanism of immunotherapy efficacy.

Both researchers are members of the Oncogene Biology Laboratory run by Julian Downward, PhD, at The Francis Crick Institute. The lab is focused on oncogenic KRAS signaling, particularly in the context of lung cancer. "KRAS is mutated in about 25% of all non-small cell lung cancers," explains

van Maldegem. "When I joined the lab, immunotherapy was just starting to become a treatment for lung cancer, so we wanted to understand more about the relationship of lung cancer to the immune system and what creates a therapeutic response."

Initially, the group used flow cytometry to characterize the tumor microenvironment in different mouse models. Van Maldegem had been developing mouse tumor models for lung cancer with varying levels of immunogenicity as a means to test different systems and examine how tumor cells interact with infiltrating and surrounding cells. But she wanted to learn more.

"Once the Crick acquired the Hyperion™ Imaging System, we took the opportunity to use that," she says. "Starting with flow cytometry enabled us to already have markers to build a panel. And with Imaging Mass Cytometry™ (IMC™), we could build just one panel instead of our usual three. While we were used to looking at large collections of cells, extending our knowledge to include where the cells are in the tissue was of great interest. So it was key to have many markers and look at all the markers in the cells at the same time."

Imaging Mass Cytometry and mouse modeling

Because they were one of the first adopters of IMC at the Crick, and also were getting set up to use mouse models, team members had to develop everything from scratch.

When creating their IMC panel, antibodies they had already validated for flow cytometry were a good place to start because they used fresh frozen tissue sections in which most epitopes are maintained in a native state. Valand notes

“With IMC, we could image our samples using more markers, allowing us to learn more from each area. ... It was beautiful to see the tumor with the normal tissue surrounding it and the way the cells were organized in the tissue.”

that “we used immunofluorescence to test clones we already were using with cells in solution for flow cytometry. For many of the antibodies that we validated, we were able to order the same clones from the Fluidigm Helios™ catalogue and used them for IMC.”

A mouse model offers a complete systemic representation that cannot be investigated in humans. When van Maldegem and Valand were ready to image their samples, they took that holistic approach by imaging whole tumors including the healthy adjacent tissue. The ability to collect information about different areas of the same tumor and compare similar areas across tumors provided a more comprehensive overview of cell behavior and tissue architecture.

“We didn’t want to miss any changes or interactions across samples, and we learned

that this was a big roadblock with other systems. With IMC, we could image our samples using more markers, allowing us to learn more from each area,” says Valand. They questioned how the tumor cells and immune cells interact and what it is about these interactions that determines the response to therapies. Examination of the whole story could allow direct comparison of cell types and spatial architecture and movement, something they had not been able to do before.

“It was beautiful to see the tumor with the normal tissue surrounding it and the way the cells were organized in the tissue. That was really an eye opener, and so using IMC became the default,” adds van Maldegem.

Hackathon success

With more samples and the ability to incorporate more markers comes more data and thus larger datasets. Valand started off with the recommended analysis pipeline using CellProfiler™ for single cell segmentation, and then incorporated ilastik for pixel classification. The large amount of data the team was generating prompted them to seek additional support for analysis.

As fortune would have it, the Crick was advertising for the first data challenge, in which labs can present an issue and are paired with bioinformatics groups to help develop creative solutions. Van Maldegem and Valand were looking to create an automated segmentation pipeline that enabled individual plug-ins that could be

“

... extending our knowledge to include where the cells are in the tissue was of great interest. It was key to have many markers and look at all the markers in the cells at the same time.”

easily customizable and moved in or out of an analysis workflow.

“It was a real game changer for us because now we could run a whole cohort in one go, instead of manually dragging input files in and out of multiple software. The new approach, once optimized for the cohort, permitted us to run images directly from the Hyperion and get single-cell expression data out in the form of a spreadsheet. That was a big advantage for us,” explains Valand.

The new automated pipeline was flexible enough to allow the team to edit which plugins were needed, optimize settings specific to the samples and automatically run from the original file straight to segmented images.

The creativity and ability to look beyond what had already been done led van Maldegem and Valand to rethink an approach that could provide new information. The use of IMC, the creation of a new antibody panel and the automated analysis pipeline brought together a whole methodology that will make this type of investigation more accessible for other scientists to use IMC in their preclinical research.

Therapy impact on tumor microenvironment

Most important, the methodology offered valuable insights into the behavior of immune cells in their response to cancer therapy. The group was able to see dramatic remodeling of the tumor microenvironment when inhibiting KRAS in the tumor cells specifically, using

novel KRAS G12C inhibitors. At a basic level, lung tumors are incredibly immune-evasive because they are very efficient at excluding immune cells from infiltrating the tumor itself.

This leaves what would be effective immune cells at the tumor periphery. When the tumors are then treated with the inhibitor, more cytotoxic T cells are able to move into the tumor core. Furthermore, they identified macrophages changing to a mature phenotype and appearing as active antigen-presenting cells. These adjustments within the tumor microenvironment could lead to a better response to immunotherapy.

“We’ve shed some light on what is happening when tumors are being treated with a therapy specifically focusing on KRAS signaling, and how important it is in orchestrating the immune suppressive microenvironment,” concludes van Maldegem.

Spatial biology is key

Based on her experience with creating such a usable and information-rich approach, van Maldegem suggests paying close attention to segmentation results. “This initial step can really influence the quality of the downstream data. If you get that right, you will get beautiful data. And I think that’s quite an important message.”

IMC was chosen “because of the spatial information that you get from it.” For example, the team had already seen several macrophage populations with their original flow cytometry studies, but there was no clarity

Most important, the methodology offered valuable insights into the behavior of immune cells in their response to cancer therapy.

about their dynamics and what their role could be. Only once they saw how these cells were arranged in tumors, with one population being in the tumor and one at the periphery, were they better able to deduce their roles and interactions. It's the cellular neighborhood and where they are that are important, not necessarily the quantity of cells.

Future experiments will involve confirming what they found in these mouse models, and also further integrating the vast IMC data with other multi-omics.

Read the publication:

Van Maldegem, F. et al. "Characterisation of tumour immune microenvironment remodelling following oncogene inhibition in preclinical studies using an optimised Imaging Mass Cytometry workflow." *bioRxiv* (2021): doi.org/10.1101/2021.02.02.429358

For Research Use Only. Not for use in diagnostic procedures.

Information in this publication is subject to change without notice. Patent and license information: fluidigm.com/legal/notices. Limited Use Label License: The purchase of this Fluidigm Instrument and/or Consumable product conveys to the purchaser the limited, nontransferable right to use with only Fluidigm Consumables and/or Instruments respectively except as approved in writing by Fluidigm. Trademarks: Fluidigm, the Fluidigm logo, Bringing new insights to life, Helios, Hyperion, Imaging Mass Cytometry, IMC and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.

©2021 Fluidigm Corporation. All rights reserved. 06/2021

See how our
Innovative
Solutions IMC
Cell Segmentation
Kit* facilitates
IMC analysis:
**fluidigm.com/
innovate**

*Innovative Solutions are custom-made, lab-tested reagents and workflows and are not part of the Maxpar® catalog.

**Bringing new
insights to life.™**